Kantonsspital Luzern, Universität Luzern
Lucerne, Switzerland
NCT Number: NCT07533578
This study investigates whether the timing of feeding expressed breast milk influences infant sleep and circadian (day-night) development in preterm infants.
In early life, infants produce very little of the hormone melatonin, which plays a key role in regulating sleep and circadian rhythms. Breast milk naturally contains melatonin, and its levels vary across the day, with higher concentrations at night. This variation may provide important biological signals that help infants develop healthy sleep-wake patterns.
However, expressed breast milk is often fed without considering the time it was expressed. This may disrupt the transfer of circadian signals from mother to infant.
The aim of this randomised controlled trial is to determine whether feeding expressed breast milk according to the time of expression (e.g. giving night-time milk at night) improves sleep consolidation and circadian development compared with usual feeding practices.
A total of 200 preterm infants born between 32+0 and 36+6 weeks' gestation who are receiving expressed breast milk will be enrolled and randomly assigned to one of two groups:
Intervention group: preterm infants receive expressed breast milk matched to the time of day it was expressed (day, evening or night)
Control group: preterm infants receive expressed breast milk without regard to timing (usual practice)
The main outcome is sleep consolidation at 6 months of age, measured objectively using actigraphy (a small wearable device that records sleep and activity). Additional outcomes include sleep patterns over time, circadian development, melatonin exposure, gut microbiota composition, and clinical outcomes such as infections and neurodevelopment.
The intervention does not involve any medication and uses the infant's usual nutrition. Risks are minimal and mainly relate to the additional effort required for milk labelling and timing.
This study will provide evidence on whether a simple, low-risk change in feeding practice can support infant sleep and early-life circadian development, with potential benefits for child health and family well-being.
Trial opening soon.
Get Notified0 day–1 month
All sexes
Interventional
Not applicable
Lucerne, Switzerland
This study investigates whether the timing of feeding expressed breast milk influences infant sleep and circadian (day-night) development in preterm infants.
In early life, infants produce very little of the hormone melatonin, which plays a key role in regulating sleep and circadian rhythms. Breast milk naturally contains melatonin, and its levels vary across the day, with higher concentrations at night. This variation may provide important biological signals that help infants develop healthy sleep-wake patterns.
However, expressed breast milk is often fed without considering the time it was expressed. This may disrupt the transfer of circadian signals from mother to infant.
The aim of this randomised controlled trial is to determine whether feeding expressed breast milk according to the time of expression (e.g. giving night-time milk at night) improves sleep consolidation and circadian development compared with usual feeding practices.
A total of 200 preterm infants born between 32+0 and 36+6 weeks' gestation who are receiving expressed breast milk will be enrolled and randomly assigned to one of two groups:
Intervention group: preterm infants receive expressed breast milk matched to the time of day it was expressed (day, evening or night) Control group: preterm infants receive expressed breast milk without regard to timing (usual practice)
The main outcome is sleep consolidation at 6 months of age, measured objectively using actigraphy (a small wearable device that records sleep and activity). Additional outcomes include sleep patterns over time, circadian development, melatonin exposure, gut microbiota composition, and clinical outcomes such as infections and neurodevelopment.
The intervention does not involve any medication and uses the infant's usual nutrition. Risks are minimal and mainly relate to the additional effort required for milk labelling and timing.
This study will provide evidence on whether a simple, low-risk change in feeding practice can support infant sleep and early-life circadian development, with potential benefits for child health and family well-being.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Expressed breast milk is labelled at the time of expression and categorised into predefined time windows:
Day milk: 06:00-17:59 Evening milk: 18:00-21:59 Night milk: 22:00-05:59 Infants are fed milk corresponding to the appropriate time-of-day window to align feeding with circadian rhythms. Caregivers receive standardised training, and adherence is monitored using feeding logs.
Expressed breast milk is fed without consideration of the time of expression. Milk handling, storage, and preparation follow standard procedures. No modification of milk composition or additional substances are introduced.
Time frame: At 6 months of age
Measured by actigraphy
Time frame: At 2, 4, 6, 12, and 24 months
Assessed by actigraphy and sleep-wake diaries
Time frame: At 2, 4, 6, 12, and 24 months
Assessed by actigraphy
Time frame: At 2, 4, 6, 12, and 24 months
Assessed using the Brief Infant Sleep Questionnaire (BISQ)
Time frame: At 2, 4, 6, 12, and 24 months
In breast milk and infant stool
Time frame: At 2, 4, 6, 12, and 24 months
Assessed by shotgun metagenomic sequencing
Time frame: At 2, 4, 6, 12, and 24 months
Clinically diagnosed infections (including otitis media and lower respiratory tract infections), assessed via medical records and parental report
Time frame: 24 months
Bayley Scales of Infant and Toddler Development (Bayley-III)
Contact information is provided by the study sponsor or research team.
Luzerner Kantonsspital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07686432
Anesthetics Adverse Reaction, Ciprofol
View Trial DetailsNCT07677930
Circadian Rhythm, Consciousness Disorders
View Trial DetailsNCT07634029
Apnea, Behavior
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07101978
Body Temperature Changes, Chronic Pain
Bern, Canton of Bern, Switzerland
View Trial Details